Garuda - Garba Rujukan Digital

Clinical-pathologic factors, as predictor of lymph nodes metastasis in cervical cancer stage IB and IIA Aziz, M. F.; Andrijono, Andrijono; Nuranna, Laila; Purbadi, Sigit; Mangunkusumo, Rukmini T.; Siregar, Budiningsih; Cornain, Santoso; Saifuddin, Abdul B.; Tjarta, Achmad; Sutrisna, Bambang
Medical Journal of Indonesia Vol 13, No 2 (2004): April-June
Publisher : Faculty of Medicine Universitas Indonesia

The aim of this study was to identify possible predictor factors of lymph node metastases in patients with cervical cancer stage IB and IIA. Study was conducted between May 1996 and December 2001. There were 183 patients of cervical cancer with FIGO Stage IB and IIA who were underwent radical hysterectomy and lymphadenectomy. From those 158 patients could be evaluated, consisting 43 patients with node metastases 115 patients without metastases. Research design was case control study. Case was patients with node metastases and control was those without node metastases. Multivariate analysis was made after bivariate analysis. On bivariate analysis age < 39 years, diameter of lesion > 4 cm, stage IIA > 4 cm, histopathology moderate and poor differentiation, blood and lymphatic vessel invasion were independent variables for node metastases with p value â¤ 0.05. However, on multivariate analysis younger age, parity â¥ 4, diameter of lesion, histopathology adenosquamous, and lymph vascular invasion (+) as independent factors for node metastases with p value â¤ 0.05. Conclusion: Younger age, parity â¥ 4, stage IIA > 4 cm, diameter of lesion, histopathology adenosquamous, and lymph vascular invasion (+) were risk factors for node metastases and can be used as predictors. (Med J Indones 2004; 13: 113-8)Keywords: cervical cancer, radical hysterectomy, node metastases, case control study, predictor

Cytokeratin 8,18 and 19 expressions, epithelial shedding, and stromal extravasation in endometrium of norethisterone enanthate (NET-EN) progestogen contraceptive users (A preliminary report) Wonodirekso, Sugito; Hadisaputra, Wachju; Affandi, Biran; Siregar, Budiningsih; Rogers, Peter A.W.
Medical Journal of Indonesia Vol 7, No 1 (1998): January-March
Publisher : Faculty of Medicine Universitas Indonesia

[no abstract available]

Fascin Expression as Prognostic Factor for Survival in Advanced Epithelial Ovarian Carcinoma Vitantri, Fara; Purbadi, Sigit; Siregar, Budiningsih; Sutrisna, Bambang
Indonesian Journal of Obstetrics and Gynecology Volume. 3, No. 4, October 2015
Publisher : Indonesian Socety of Obstetrics and Gynecology

Objective: To evaluate fascin expression as a prognostic factor and its correlation with survival and clinicopathologic factors (degree of differentiation and stage) in epithelial ovarian carcinoma. Methods: This study is prognostic study with historical cohort design. Fascin was analyzed in paraffin block sections of 33 advanced stage ovarian carcinoma patients using immunohistochemistry. Fascin expression was tested for its correlation with overall survival as well as with grade and stage of the cancer. Results: In this study, fascin expression has no correlation with survival. In the period of 17-22 months, samples with high fascin expression had a HR of 1.59 (95% CI=0.38-6.67, p=0.449), but in the period of 17-23 months, both groups had comparable HR. In the period of more than 23 months, samples with high expression of fascin had a better HR of 0.40 (95% CI=0.04-4.38, p=0.449). No significant correlation was found between fascin expression with grade (OR=2.08, 95% CI=0.44-9.84, p=0.442) and stage (OR=2.70, 95% CI=0.39-18.96, p=0.360). Conclusion: In this study, there was no correlation between fascin expression and survival, and also no correlation between fascin, grade and stage. Further study with a larger, more homogenous sample, analyzing confounding factors is needed. [Indones J Obstet Gynecol 2015; 3-4: 222-229] Keywords: advanced stage ovarian carcinoma, fascin, survival

CD133, CD44, and ALDH1A1 as cancer stem cell markers and prognostic factors in epithelial ovarian cancer Andrijono, Andrijono; Sutrisna, Bambang; Harahap, Alida Roswita; Kanoko, Mpu; Nuranna, Laila; Siregar, Budiningsih; Wulandari, Dewi; Pelupessy, Nugraha Utama
Medical Journal of Indonesia Vol 28, No 1 (2019): March
Publisher : Faculty of Medicine Universitas Indonesia

BACKGROUND Ovarian cancer is a heterogeneous disease, and most patients are diagnosed at an advanced stage. Epithelial ovarian cancer type II is characterized by rapid tumor growth and is genetically more labile than type I. This study was aimed to demonstrate the prognostic value of CSC by using the markers CD133, CD44, and ALDH1A1 in EOC.METHODS Clinicopathological and demographic data were collected from medical records. The markers CD133, CD44, and ALDH1A1 were examined with flow cytometry and immunohistochemistry. Cancer stem cell (CSC) marker expression in patients with ovarian cancer types I and II were related to chemotherapy and survival. In multivariate analysis, the prognosis model was tested for ten months.RESULTS The largest demographic consisted of patients aged ≥45 years, with stage I, poor differentiation, and type II, of which there were 40 samples (72.7%), 23 samples (41.8%), 30 samples (54.5%), and 16 samples (29.1%), respectively. There is a high correlation between the 10-month chemotherapy response and the 4 variables, i.e., age ≥45 years, type II, stage III–IV, and CD44, with an ROC of 80.75% and a post-test probability of 82.5%. Using the ROC curve, the highest chemoresistance score was 0.841, based on the combination of CSCs markers and clinicopathological factors, that is stage III–IV, age ≥45 years, poor differentiation, type II, negative CD133, high CD44, and high ALDH1A1.CONCLUSIONS CSC (CD133, CD44, and ALDH1A1) markers and clinicopathological factors are prognostic of epithelial ovarian cancer.

Fascin Expression as Prognostic Factor for Survival in Advanced Epithelial Ovarian Carcinoma Vitantri, Fara; Purbadi, Sigit; Siregar, Budiningsih; Sutrisna, Bambang
Indonesian Journal of Obstetrics and Gynecology Volume. 3, No. 4, October 2015
Publisher : Indonesian Socety of Obstetrics and Gynecology

Objective: To evaluate fascin expression as a prognostic factor and its correlation with survival and clinicopathologic factors (degree of differentiation and stage) in epithelial ovarian carcinoma. Methods: This study is prognostic study with historical cohort design. Fascin was analyzed in paraffin block sections of 33 advanced stage ovarian carcinoma patients using immunohistochemistry. Fascin expression was tested for its correlation with overall survival as well as with grade and stage of the cancer. Results: In this study, fascin expression has no correlation with survival. In the period of 17-22 months, samples with high fascin expression had a HR of 1.59 (95% CI=0.38-6.67, p=0.449), but in the period of 17-23 months, both groups had comparable HR. In the period of more than 23 months, samples with high expression of fascin had a better HR of 0.40 (95% CI=0.04-4.38, p=0.449). No significant correlation was found between fascin expression with grade (OR=2.08, 95% CI=0.44-9.84, p=0.442) and stage (OR=2.70, 95% CI=0.39-18.96, p=0.360). Conclusion: In this study, there was no correlation between fascin expression and survival, and also no correlation between fascin, grade and stage. Further study with a larger, more homogenous sample, analyzing confounding factors is needed. [Indones J Obstet Gynecol 2015; 3-4: 222-229] Keywords: advanced stage ovarian carcinoma, fascin, survival

Caspase-3 can not be Used to Predict the Response to Neoadjuvant Chemotherapy Regiment PVB in Cervical Cancer Stage IB-IIA Ambari, Ediwibowo; Winarto, Hariyono; Sutrisna, Bambang; Siregar, Budiningsih
Indonesian Journal of Obstetrics and Gynecology Volume. 1, No. 3, July 2013
Publisher : Indonesian Socety of Obstetrics and Gynecology

Objectives: To determine the factors that may be used as the prognostic parameter for the therapeutic efficacy of neoadjuvant chemotherapy, which can be used to revising the management of early stage cervical cancer patients with large lesions. Methods: This was a retrospective cohort study. The study was conducted in the Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, University of Indonesia. The subjects were 15 cervical cancer stage IB2 and IIA patients with lesions’ size of > 4 cm, who would be treated with neoadjuvant chemotherapy, consisted of cisplatin 50 mg/m2, vincristine 2 mg/m2 and bleomycin 15 mg regiment. The patients’ response would be evaluated after completing 3 series of chemotherapy. Data was retrieved from medical records and cervical biopsy paraffin blocks and examined histopathologically using IHC staining to see expression of caspase-3 with histoscore assessment score. Data was analyzed by univariate, bivariate analysis. Results: Response to PVB neoadjuvant chemotherapy was found in 5 out of 15 patients. None of the clinicopathology variables can be used to predict response to therapy. Expression of caspase-3 as a marker of apoptosis, can not predict the response of the therapy before administrating neoadjuvant chemotherapy either. There is a significant difference between the levels of caspase-3 in epidermoid carcinoma with adenocarcinoma, with p value of 0.02 (RR 6;95% CI 1.69-21.26). Conclusion: Clinicopathologic factors and the expression of caspase-3 before getting chemotherapy neoadjuvant can not predict the succeed of the therapy. [Indones J Obstet Gynecol 2013; 1-3: 156-60] Keywords: caspase -3, clinicopathologic, early-stage cervical cancer lession in large, neoadjuvant chemotherapy response to therapy

Title

Found 6 Documents
Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title Search

Found 6 Documents Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 6 Documents
Search